Fig. 3
From: Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia
HHT and APG-2575 combination exerts synergistically anti-leukemic effect in primary AML samples. A Cell viability of AML patients treated with APG-2575 or HHT single agent or their combination for 48 h. The CI indexes (down panel) were calculated by CalcuSyn software. B The apoptosis of primary AML samples treated with APG-2575 and HHT single agent or their combination for 24 h. (One-way ANOVA, combination treatments versus control and single treatments, *P < 0.05; **P < 0.01; ***P < 0.001). C Cell viability was calculated for every dose combination of APG-2575 and HHT using the SynergyFinder Web application. Synergy score: < − 10, antagonistic; from − 10 to 10, additive; > 10, synergistic